2023-510544-21-00RecruitingPhase 1
INtra-tumor miCro dosIng in PatIents with advanced malignant mElanoma receiving aNti-PD1 Therapy. A pilot study.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 18 Jun 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 4 (estimated)
- First submitted
- 2 Jul 2024
- Start date
- 18 Feb 2025
- Lead sponsor
- UZ Leuven
- Diseases
- Melanoma
- EU CT number
- 2023-510544-21-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 4
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced malignant melanoma who receive anti-PD1 therapy.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Advanced malignant melanoma.
- Earlier treatment
- People receive anti-PD1 therapy.
Read by machine on 9 Nov 2026.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UZ Leuven | Leuven | Belgium | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.